ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, June 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the Company's common shares to three new employees on June 3, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.
瑞士洛桑，2024年6月3日（环球新闻通讯社） - ADC Therapeutics SA（纽交所：ADCT）今天宣布，公司已授予期权，于2024年6月3日向三名新员工购买公司共计109,800股普通股（每个股权奖励称为“授予”）。这些授予作为员工就业的重要诱因而提供。董事会的薪酬委员会根据公司的诱因计划批准了这些授予，以激励和奖励受让人以最高水平表现，并为公司的成功做出重要贡献。这些授予是依据纽交所所列公司手册规则303A. 08下的就业诱因豁免条款进行的。公司根据规则303A.08发布了这份新闻稿。这些授予将于授予日首个周年时行使和行使25％，之后每月授予日的股权奖励数量的1/48，以便于在授予日的第四个周年时整个奖励都授予，并继续在公司工作。